Cesková E, Svestka J
Psychiatric Department, Masaryk University, Brno, Czech Republic.
Pharmacopsychiatry. 1993 Jul;26(4):121-4.
A double-blind eight-week study was carried out to compare the efficacy and safety of risperidone in relation to haloperidol. Sixty-two inpatients suffering from acute schizophrenic or schizoaffective psychoses diagnosed according to ICD-9 were treated with risperidone 2-20 mg daily or haloperidol 2-20 mg daily. The mean total BPRS scores were reduced from 45.5 to 32.4 in the risperidone group and from 43.1 to 28.5 in haloperidol group. There were no significant differences between the two treated groups with regard to the total BPRS score and the percentage of remissions achieved. No statistically significant difference was found between the groups in any of the factors or items except guilt feeling (p < 0.02), anxiety (p < 0.005), and factor I--anxiety/depression--(p < 0.02) in favour of haloperidol. Risperidone had the benefit of a lower incidence of extrapyramidal side-effects.
一项双盲、为期八周的研究开展，以比较利培酮相对于氟哌啶醇的疗效和安全性。62名根据ICD - 9诊断为急性精神分裂症或分裂情感性精神病的住院患者，分别接受每日2 - 20毫克利培酮或每日2 - 20毫克氟哌啶醇治疗。利培酮组的BPRS总分均值从45.5降至32.4，氟哌啶醇组从43.1降至28.5。在总BPRS评分及缓解率方面，两个治疗组之间无显著差异。除了罪恶感（p < 0.02）、焦虑（p < 0.005）和因子I（焦虑/抑郁，p < 0.02）有利于氟哌啶醇外，两组在任何因素或项目上均未发现统计学显著差异。利培酮的优势在于锥体外系副作用的发生率较低。
